Table 1.
Clinical data for the HIV-IBM, sIBM and healthy control group (NDC)
| HIV-IBM | sIBM | NDC | |
|---|---|---|---|
| Sex | |||
| ♀ | – | 14% (n = 1) | 17% (n = 1) |
| ♂ | 100% (n = 7) | 86% (n = 6) | 83% (n = 5) |
| Age at IBM diagnosis/biopsy (years) | |||
| Mean (± SD) | 53 (± 4.7) | 70 (± 4.3) | 58 (± 9.5) |
| Onset of symptoms before biopsy (years) | |||
| Mean (± SD) | 1.7 (± 0.7) | 6.2 (± 3.2) | |
| First symptom | |||
| Myalgia | 14% (n = 1) | – | |
| Weakness upper extemities | – | 14% (n = 1) | |
| Weakness lower extremities | 57% (n = 4) | 57% (n = 4) | |
| Dysphagia | – | 14% (n = 1) | |
| No data | 29% (n = 2) | 14% (n = 1) | |
| Distribution of weakness | |||
| Distal > proximal upper extremity | 14% | 29% | |
| Proximal > distal lower extremity | 57% | 72% | |
| No data | 43% | 14% | |
| CK (U/l) | |||
| Mean (± SD) | 802 (± 241) | 846 (± 289) | |
| Anti-cN1A | |||
| Positive | – | 29% (n = 2) | |
| Negative | 57% (n = 4) | 42% (n = 3) | |
| No data | 43% (n = 3) | 29% (n = 2) | |
| Drug therapy | |||
| Steroids | – | – | |
| IVIG | 42% (n = 3) | 86% (n = 6) | |
| None | 29% (n = 2) | – | |
| No data | 29% (n = 2) | 14% (n = 1) | |
| Treatment response (*incl. temporary) | |||
| Yes* | 67% (n = 2) | 100% (n = 6) | |
| No | – | – | |
| No data | 13% (n = 1) | – | |
| Age at HIV diagnosis | |||
| Mean (± SD) | 40 (± 10.5) | ||
| CD4 nadir (CD4+ T cells/µl) | |||
| < 200 | 29% (n = 2) | ||
| 200–500 | 14% (n = 1) | ||
| > 500 | – | ||
| No data | 57% (n = 4) | ||
| Years between HIV diagnosis and biopsy | |||
| Mean (± SD) | 12 (± 7.5) | ||
| ART at muscle biopsy | |||
| Yes | 72% (n = 5) | ||
| No | 14% (n = 1) | ||
| No data | 14% (n = 1) | ||
| History of Zidovudine use | |||
| Yes | – | ||
| No | 57% (n = 4) | ||
| No data | 43% (n = 3) | ||
| HIV-associated co-infections | |||
| Hepatitis B | 29% (n = 2) | ||
| Lues | – | ||
| Chlamydia | – | ||
| None | – | ||
| No data | 71% (n = 5) | ||
| Other HIV-associated diseases (multiple answers possible) | |||
| Malignoma | 14% (n = 1) | ||
| Opportunistic infections | 14% (n = 1) | ||
| Neuropathy | 29% (n = 2) | ||
| None | 14% (n = 1) | ||
| No data | 57% (n = 4) |